BioCentury | Jun 19, 2020
Product Development

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

After dexamethasone set a new bar for mortality reduction in COVID-19 patients this week, InflaRx and Kiniksa reported data from their anti-inflammatory mAbs showing trends toward a survival benefit. InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BioCentury | Apr 2, 2020
Product Development

COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more

EMA said Wednesday that chloroquine and hydroxychloroquine should only be used to treat COVID-19 in clinical trials or national emergency use programs to preserve availability for autoimmune indications, such as lupus. The agency’s statement came...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...and the company expects to continue exploring the cardiometabolic area. Diabetes drug Januvia sitagliptin, a DPP-4...
...will come from outside the U.S. Targets Btk - Bruton’s tyrosine kinase DPP-4 (CD26) - Dipeptidyl peptidase-4...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BioCentury | Jan 29, 2020
Politics & Policy

Industry leaders applaud CVS zero co-pay diabetes drug access

...the RxZERO plan extends to most other diabetes medications, including SGLT2 inhibitors, GLP-1R agonists and DPP-4...
...added. Targets: SGLT2 - Sodium-glucose cotransporter 1; GLP-1R (GLP1R) - Glucagon-like peptide-1; DPP-4 (CD26) - Dipeptidyl peptidase-4 Lauren...
BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

...BioCentury in an emailed statement. China patents on Type II diabetes therapy Onglyza saxagliptin, a DPP-4...
...of the listed patents. Source: China Listed Drug Catalog Database   Targets DPP-4 (CD26) - dipeptidyl peptidase-4 Steve...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

...stimulating insulin release, or promoting glucose excretion or uptake -- mechanisms employed by GLP-1R agonists, DPP-4...
...agonists and SGLT2 inhibitors, respectively. Chinese patients have access to GLP-1R agonists and SGLT2 and DPP-4...
...the principal reason why our pipeline includes so many combination trials.” Targets DPP-4 (CD26) - Dipeptidyl peptidase-4...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...wholesale acquisition cost (WAC) of $772.43 per month. Oral diabetes drug competitors Januvia sitagliptin, a DPP-4...
...are already collaborating on an AI solution to monitor liver cancer. Targets: DPP-4 (CD26) - Dipeptidyl peptidase-4...
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...used to support development of the company’s small molecule pipeline including lead candidate cetagliptin, a DPP-4...
...round. Prellis develops 3-D tissue scaffolds for R&D and organ transplantation. Targets: DPP-4 (CD26) - Dipeptidyl peptidase-4...
...ErbB1; HER1) - Epidermal growth factor receptor BioCentury Staff Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. Prellis Biologics Inc. RAPT Therapeutics Inc. Dipeptidyl peptidase-4 (DPP-4) (CD26) CGeneTech...
Items per page:
1 - 10 of 825